Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 603

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 603
---
 platform. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The accounting policies of the biotech segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotech segment based on net loss, which is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. As such, the CODM uses cash forecast models in deciding how to invest into the biotech segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with cash forecast models.

 F-18 

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:   Year Ended  Year Ended   December 31,   December 31,    2024  2023 Operating Expenses      Research and development $3,190,293  $5,003,695 Sales and marketing  571,040   820,554 General and administrative  7,055,814   4,696,486 Total operating expenses  10,817,147   10,520,735          Operating loss  (10,817,147)  (10,520,735)Other segment items (a)  (690,800)  460,485          Net loss $(11,507,947) $(10,060,250)         Reconciliation of net loss        Adjustments and reconciling items  -   - Consolidated net loss $(11,507,947) $(10,060,250) (a) Other segment items included in segment loss includes warrant expense, changes in warrant liability, gain on settlement of warrant liability and interest income.

Note 14 - Subsequent Events The Company has evaluated events through, March 31, 2025, the filing date